Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | AREN0321 and AREN03B2: treatment of focal anaplastic Wilms tumor (FAWT)

Amy Armstrong, MD, Washington University School of Medicine, St. Louis, MO, shares an overview of a report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies (NCT00335556) evaluating whether intensifying therapy for stage I and IV focal anaplastic Wilms tumor (FAWT) would improve survival of these patients. Patients with stage I-III FAWT enrolled in AREN0321 received a chemotherapy regimen called DD4A, while those with stage IV FAWT received vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and radiation (UH-1). The results showed excellent survival rates for patients with stage I and II FAWT treated with DD4A and radiation. Stage III FAWT patients may benefit from intensified therapy, while stage IV FAWT patients experienced improved survival but with an increased risk of toxicity. Strategies to mitigate the toxicity of UH-1 therapy have been implemented in ongoing trials. The findings suggest the potential for improved treatment approaches in FAWT. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.